(Q30749776)

26 June 2017

1 reference

title

Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer's disease (English)

1 reference

26 June 2017

0 references

1 reference

Gary W Small

1

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Advanced Drug Delivery Reviews

26 June 2017

published in

1 reference

26 June 2017

volume

54

1 reference

26 June 2017

issue

12

1 reference

26 June 2017

page(s)

1561-1566

1 reference

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Mild cognitive impairment represents early-stage Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Childhood mental ability and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Hippocampal formation size predicts declining memory performance in normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded "stress test" during PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Separate neural bases of two fundamental memory processes in the human medial temporal lobe.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Patterns of brain activation in people at risk for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

Scintigraphy with 123I-serum amyloid P component in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900151-5

7 January 2021

10.1016/S0169-409X(02)00151-5

Identifiers

DOI

1 reference

26 June 2017

1 reference